Share-based Payment Arrangement, Expense of Fortress Biotech, Inc. from 31 Mar 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Fortress Biotech, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2015 to 30 Sep 2025.
  • Fortress Biotech, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,197,000, a 51% decline year-over-year.
  • Fortress Biotech, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $42,470,000, a 111% increase year-over-year.
  • Fortress Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $32,619,000, a 92% increase from 2023.
  • Fortress Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17,029,000, a 26% decline from 2022.
  • Fortress Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22,987,000, a 18% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Fortress Biotech, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $42,470,000 $3,197,000 -$3,376,000 -51% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $45,846,000 $16,793,000 +$11,795,000 +236% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $34,051,000 $6,289,000 +$1,432,000 +29% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $32,619,000 $16,191,000 +$12,487,000 +337% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $20,132,000 $6,573,000 +$2,196,000 +50% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $17,936,000 $4,998,000 +$781,000 +19% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $17,155,000 $4,857,000 +$126,000 +2.7% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $17,029,000 $3,704,000 -$1,802,000 -33% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $18,831,000 $4,377,000 -$2,460,000 -36% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $21,291,000 $4,217,000 -$864,000 -17% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $22,155,000 $4,731,000 -$832,000 -15% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $22,987,000 $5,506,000 -$1,531,000 -22% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $24,518,000 $6,837,000 +$2,511,000 +58% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $22,007,000 $5,081,000 +$731,000 +17% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $21,276,000 $5,563,000 +$1,790,000 +47% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $19,486,000 $7,037,000 +$3,905,000 +125% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $15,581,000 $4,326,000 +$1,155,000 +36% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $14,426,000 $4,350,000 +$602,000 +16% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $13,824,000 $3,773,000 +$373,000 +11% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $13,451,000 $3,132,000 +$367,000 +13% 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q3 2020 $13,084,000 $3,171,000 -$570,000 -15% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $13,654,000 $3,748,000 +$375,000 +11% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $13,279,000 $3,400,000 +$91,000 +2.8% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q4 2019 $13,188,000 $2,765,000 01 Oct 2019 31 Dec 2019 10-K/A 09 Apr 2021 2020 FY
Q3 2019 $3,741,000 -$365,000 -8.9% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $3,373,000 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $3,309,000 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q3 2018 $4,106,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q1 2016 $1,100,000 -$1,900,000 -63% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q1 2015 $3,000,000 01 Jan 2015 31 Mar 2015 10-K 15 Mar 2016 2015 FY

Fortress Biotech, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $32,619,000 +$15,590,000 +92% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $17,029,000 -$5,958,000 -26% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $22,987,000 +$3,501,000 +18% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $19,486,000 +$6,035,000 +45% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $13,451,000 +$263,000 +2% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
2019 $13,188,000 -$1,824,000 -12% 01 Jan 2019 31 Dec 2019 10-K/A 09 Apr 2021 2020 FY
2018 $15,012,000 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
2015 $3,300,000 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.